Table 1.
Patient and HCT Characteristics
| Variable | MAC and Low/Intermediate risk | RIC and Low/Intermediate risk | MAC and High/Very High risk | RIC and High/Very High Risk |
|---|---|---|---|---|
| Number of patients | 1539 | 999 | 1121 | 728 |
| Number of centers | 100 | 105 | 100 | 95 |
| Age at HCT, years | ||||
| Median (range) | 53 (40–65) | 59 (40–65) | 55 (40–65) | 60 (40–65) |
| 40–50 | 620 (40) | 167 (17) | 347 (31) | 80 (11) |
| 51–60 | 768 (50) | 470 (47) | 583 (52) | 355 (49) |
| 61–65 | 151 (10) | 362 (36) | 191 (17) | 293 (40) |
| Recipient Sex | ||||
| Male | 781 (51) | 553 (55) | 639 (57) | 426 (59) |
| Female | 758 (49) | 446 (45) | 482 (43) | 302 (41) |
| Karnofsky score | ||||
| <90 | 525 (34) | 398 (40) | 498 (44) | 367 (50) |
| ≥90 | 991 (64) | 588 (59) | 594 (53) | 357 (49) |
| Missing | 23 (1) | 13 (1) | 29 (3) | 4 (<1) |
| HCT-CI | ||||
| 0 | 398 (26) | 198 (20) | 227 (20) | 107 (15) |
| 1 | 229 (15) | 153 (15) | 150 (13) | 96 (13) |
| 2 | 240 (16) | 129 (13) | 146 (13) | 89 (12) |
| 3 | 308 (20) | 187 (19) | 221 (20) | 120 (16) |
| 4 | 167 (11) | 122 (12) | 148 (13) | 91 (13) |
| ≥5 | 192 (12) | 201 (20) | 219 (20) | 215 (30) |
| Missing | 5 (0) | 9 (1) | 10 (1) | 10 (1) |
| Disease | ||||
| AML | 1294 (84) | 800 (80) | 606 (54) | 285 (39) |
| MDS | 245 (16) | 199 (20) | 515 (46) | 443 (61) |
| Disease status prior to HCT for AML | ||||
| Primary induction failure | 0 | 0 | 277 (25) | 113 (16) |
| CR1 | 940 (61) | 601 (60) | 118 (11) | 86 (12) |
| CR2 | 335 (22) | 188 (19) | 13 (1) | 7 (<1) |
| ≥CR3 | 19 (1) | 11 (1) | 0 | 3 (<1) |
| Relapse | 0 | 0 | 198 (18) | 76 (10) |
| Disease status prior to HCT for MDS | ||||
| MDS early | 174 (11) | 152 (15) | 68 (6) | 89 (12) |
| MDS advanced | 71 (5) | 47 (5) | 447 (40) | 354 (49) |
| WBC at diagnosis, (x 10^9) AML only* | ||||
| Median (range) | 10 (<1–450) | 7 (<1–428) | 6 (<1–399) | 5 (<1–375) |
| ≤ 10 | 602 (47) | 403 (50) | 347 (57) | 172 (60) |
| 11 – 100 | 437 (34) | 240 (30) | 163 (27) | 69 (24) |
| > 100 | 127 (10) | 62 (8) | 40 (7) | 18 (6) |
| Missing | 128 (10) | 95 (12) | 56 (9) | 26 (9) |
| Donor type | ||||
| HLA-identical sibling | 534 (35) | 228 (23) | 356 (32) | 191 (26) |
| Other relative | 71 (5) | 113 (12) | 62 (6) | 68 (9) |
| Well-matched (8/8) unrelated | 633 (41) | 340 (34) | 497 (44) | 284 (39) |
| Unrelated (≤7/8) and matching unknown | 133 (9) | 87 (9) | 114 (10) | 78 (11) |
| Umbilical cord blood | 168 (11) | 231 (23) | 92 (8) | 107 (15) |
| Donor/recipient sex match | ||||
| Male-Male | 501 (33) | 355 (36) | 407 (36) | 266 (37) |
| Male-Female | 436 (28) | 251 (25) | 310 (28) | 170 (23) |
| Female-Male | 276 (18) | 194 (19) | 232 (21) | 155 (21) |
| Female-Female | 320 (21) | 186 (19) | 171 (15) | 130 (18) |
| Missing | 6 (<1) | 13 (1) | 1 (<1) | 7 (<1) |
| Donor/Recipient CMV serostatus | ||||
| Recipient + | 986 (64) | 642 (64) | 716 (64) | 472 (65) |
| Recipient −/Donor − | 354 (23) | 210 (21) | 277 (25) | 173 (24) |
| Other | 199 (13) | 147 (15) | 128 (11) | 83 (11) |
| Conditioning regimen | ||||
| TBI/Cy ± Flu | 382 (25) | 259 (26) | 211 (19) | 125 (17) |
| TBI/Other | 68 (4) | 71 (7) | 59 (4) | 82 (11) |
| Bu/Cy | 476 (31) | - | 345 (31) | - |
| Bu/Flu ± TT | 531 (34) | 358 (36) | 422 (37) | 252 (35) |
| Flu/Mel ± TT | 24 (2) | 271 (27) | 21 (2) | 233 (32) |
| Other | 58 (3) | 40 (4) | 63 (5) | 36 (3) |
| ATG/Alemtuzumab | ||||
| Yes | 344 (22) | 322 (32) | 259 (23) | 247 (34) |
| No | 1191 (77) | 673 (67) | 862 (77) | 481 (66) |
| Missing | 4 (<1) | 4 (<1) | 0 | 0 |
| GVHD prophylaxis | ||||
| TCD/CD34 selected | 41 (3) | 35 (4) | 20 (2) | 26 (4) |
| Tac + MMF/MTX +/− others | 1250 (81) | 653 (65) | 940 (84) | 505 (69) |
| CSA + MMF/MTX +/− others | 187 (12) | 194 (19) | 105 (9) | 116 (16) |
| PT-Cy + others | 37 (2) | 75 (8) | 46 (4) | 48 (7) |
| Others/Missing | 24 (2) | 42 (4) | 10 (<1) | 33 (5) |
| Graft source | ||||
| Bone marrow | 181 (12) | 105 (11) | 132 (12) | 73 (10) |
| Peripheral blood | 1190 (77) | 663 (66) | 897 (80) | 548 (75) |
| Umbilical cord blood | 168 (11) | 231 (23) | 92 (8) | 107 (15) |
| Year of transplant | ||||
| 2009–2012 | 893(58) | 415 (42) | 610 (54) | 290 (39) |
| 2013–2015 | 646 (42) | 584 (59) | 511 (46) | 438 (61) |
| Median follow-up of survivors (range), months | 50 (4–98) | 37 (3–103) | 47 (3–98) | 38 (1–97) |
HR, hazard ratio. RIC, reduced-intensity conditioning. MAC, myeloablative conditioning. L/I, low/intermediate risk disease risk index (DRI). High-risk, high/very high risk DRI. HCT-CI, hematopoietic cell transplant comorbidity index.